Topic: fatty liver disease
Gemphire is cutting its staff in a bid to cut costs after the FDA requested more preclinical data for its only drug, gemcabene.
Viking Therapeutics’ lead lipid disorder asset met its endpoints in a midstage trial, dropping cholesterol and liver fat levels in patients with NAFLD.
Gemphire is halting a midphase trial testing gemcabene in pediatric nonalcoholic fatty liver disease because some patients’ disease got worse.
Using an old Roche drug, Madrigal Pharmaceuticals has seen its stock soar 130% on its latest fatty liver disease trials data.
Scientists at Duke have identified a pathway in the liver that they believe could be manipulated to reduce the deposition of fat in the liver, as well as glucose regulation.
The round reunites some of the executives and investors who helped Dezima and Akarna to takeovers by Amgen and Allergan, respectively.
Metacrine is adding to this week's NASH talk after getting off a series B as it aims to combat the fatty liver disorder.
Madrigal Pharmaceuticals has seen some positive snapshot data coming out of its phase 2 fatty liver disease test using an old Roche drug.
In new phase 2 data published today, Gilead says a higher dose of its NASH drug saw statistically significant reductions in liver fat.
CymaBay has taken a look at its ongoing midstage test for its liver med seladelpar, and is happy with what it sees.